Nektar Therapeutics

The US FDA has voted down Nektar Therapeutics’ opioid painkiller NKTR-181, designed to treat lower back pain.  The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee unanimously has decided not to recommend the use of the painkiller, ta...

Ionis pharmaceuticals recently licensed-out its antisense drug to AstraZeneca in deal total worth up to USD 330 million Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee. AstraZeneca will now be taking care of the develo...